These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37099736)

  • 1. Adagrasib in Advanced Solid Tumors Harboring a
    Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S
    J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
    Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
    J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
    [No Abstract]   [Full Text] [Related]  

  • 3. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
    Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
    N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adagrasib: a novel inhibitor for
    Guo MZ; Marrone KA; Spira A; Rosner S
    Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated
    Yaeger R; Weiss J; Pelster MS; Spira AI; Barve M; Ou SI; Leal TA; Bekaii-Saab TS; Paweletz CP; Heavey GA; Christensen JG; Velastegui K; Kheoh T; Der-Torossian H; Klempner SJ
    N Engl J Med; 2023 Jan; 388(1):44-54. PubMed ID: 36546659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
    Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
    JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS
    Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
    N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adagrasib: First Approval.
    Dhillon S
    Drugs; 2023 Feb; 83(3):275-285. PubMed ID: 36763320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotorasib for Lung Cancers with
    Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
    N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of KRAS
    Dang S; Zhang S; Zhao J; Li W
    World J Surg Oncol; 2024 Jul; 22(1):182. PubMed ID: 39010022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Garsorasib in patients with KRAS
    Li Z; Dang X; Huang D; Jin S; Li W; Shi J; Wang X; Zhang Y; Song Z; Zhang J; Zhuang W; Liu X; Jiang L; Meng X; Zhao M; Zhou J; Zhang L; Wang P; Luo H; Yang J; Cang S; Wang X; Zhang L; Lu S;
    Lancet Respir Med; 2024 Aug; 12(8):589-598. PubMed ID: 38870979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
    de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
    Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a
    Sacher A; LoRusso P; Patel MR; Miller WH; Garralda E; Forster MD; Santoro A; Falcon A; Kim TW; Paz-Ares L; Bowyer S; de Miguel M; Han SW; Krebs MG; Lee JS; Cheng ML; Arbour K; Massarelli E; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Dharia NV; Schutzman JL; Desai J;
    N Engl J Med; 2023 Aug; 389(8):710-721. PubMed ID: 37611121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired Resistance to KRAS
    Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
    N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes following KRAS
    Chen QA; Lin WH; Zhou XX; Cao Z; Feng XL; Gao YB; He J
    Pharmacol Res; 2024 Feb; 200():107060. PubMed ID: 38185210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC.
    Brazel D; Nagasaka M
    Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS
    Li Z; Song Z; Zhao Y; Wang P; Jiang L; Gong Y; Zhou J; Jian H; Dong X; Zhuang W; Cang S; Yang N; Fang J; Shi J; Lu J; Ma R; Wu P; Zhang Y; Song M; Xu CW; Shi Z; Zhang L; Wang Y; Wang X; Zhang Y; Lu S
    J Thorac Oncol; 2023 Jul; 18(7):940-951. PubMed ID: 36948246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.